Search

Your search keyword '"Tripodi, Marie-Francoise"' showing total 105 results
Start Over Author "Tripodi, Marie-Francoise"
105 results on '"Tripodi, Marie-Francoise"'

1. Infective Endocarditis in Patients on Chronic Hemodialysis

Author

Clara, Liliana, Sanchez, Marisa, Casabé, José, Cortes, Claudia, Nacinovich, Francisco, Oses, Pablo Fernandez, Ronderos, Ricardo, Sucari, Adriana, Thierer, Jorge, Altclas, Javier, Kogan, Silvia, Spelman, Denis, Athan, Eugene, Harris, Owen, Kennedy, Karina, Tan, Ren, Gordon, David, Papanicolas, Lito, Korman, Tony, Kotsanas, Despina, Dever, Robyn, Jones, Phillip, Konecny, Pam, Lawrence, Richard, Rees, David, Ryan, Suzanne, Feneley, Michael P., Harkness, John, Post, Jeffrey, Reinbott, Porl, Gattringer, Rainer, Wiesbauer, Franz, Andrade, Adriana Ribas, Passos de Brito, Ana Cláudia, Guimarães, Armenio Costa, Grinberg, Max, Mansur, Alfredo José, Siciliano, Rinaldo Focaccia, Varejao Strabelli, Tania Mara, Campos Vieira, Marcelo Luiz, de Medeiros Tranchesi, Regina Aparecida, Paiva, Marcelo Goulart, Fortes, Claudio Querido, de Oliveira Ramos, Auristela, Weksler, Clara, Ferraiuoli, Giovanna, Golebiovski, Wilma, Lamas, Cristiane, Karlowsky, James A., Keynan, Yoav, Morris, Andrew M., Rubinstein, Ethan, Jones, Sandra Braun, Garcia, Patricia, Cereceda, M., Fica, Alberto, Mella, Rodrigo Montagna, Fernandez, Ricardo, Franco, Liliana, Gonzalez, Javier, Jaramillo, Astrid Natalia, Barsic, Bruno, Bukovski, Suzana, Krajinovic, Vladimir, Pangercic, Ana, Rudez, Igor, Vincelj, Josip, Freiberger, Tomas, Pol, Jiri, Zaloudikova, Barbora, Ashour, Zainab, El Kholy, Amani, Mishaal, Marwa, Osama, Dina, Rizk, Hussien, Aissa, Neijla, Alauzet, Corentine, Alla, Francois, Campagnac, CHU Catherine, Doco-Lecompte, Thanh, Selton-Suty, Christine, Casalta, Jean-Paul, Fournier, Pierre-Edouard, Habib, Gilbert, Raoult, Didier, Thuny, Franck, Delahaye, Francois, Delahaye, Armelle, Vandenesch, Francois, Donal, Erwan, Donnio, Pierre Yves, Flecher, Erwan, Michelet, Christian, Revest, Matthieu, Tattevin, Pierre, Chevalier, Florent, Jeu, Antoine, Rémadi, Jean Paul, Rusinaru, Dan, Tribouilloy, Christophe, Bernard, Yvette, Chirouze, Catherine, Hoen, Bruno, Leroy, Joel, Plesiat, Patrick, Naber, Christoph, Neuerburg, Carl, Mazaheri, Bahram, Sophia Athanasia, Carl Neuerburg, Deliolanis, Ioannis, Giamarellou, Helen, Thomas, Tsaganos, Giannitsioti, Efthymia, Mylona, Elena, Paniara, Olga, Papanicolaou, Konstantinos, Pyros, John, Skoutelis, Athanasios, Papanikolaou, Konstantinos, Sharma, Gautam, Francis, Johnson, Nair, Lathi, Thomas, Vinod, Venugopal, Krishnan, Hannan, Margaret M., Hurley, John P., Wanounou, Maor, Gilon, Dan, Israel, Sarah, Korem, Maya, Strahilevitz, Jacob, Durante-Mangoni, Emanuele, Iossa, Domenico, Orlando, Serena, Ursi, Maria Paola, Pafundi, Pia Clara, D’Amico, Fabiana, Bernardo, Mariano, Cuccurullo, Susanna, Dialetto, Giovanni, Covino, Franco Enrico, Manduca, Sabrina, Della Corte, Alessandro, De Feo, Marisa, Tripodi, Marie Françoise, Cecchi, Enrico, De Rosa, Francesco, Forno, Davide, Imazio, Massimo, Trinchero, Rita, Grossi, Paolo, Lattanzio, Mariangela, Toniolo, Antonio, Goglio, Antonio, Raglio, Annibale, Ravasio, Veronica, Rizzi, Marco, Suter, Fredy, Carosi, Giampiero, Magri, Silvia, Signorini, Liana, Kanafani, Zeina, Kanj, Souha S., Sharif-Yakan, Ahmad, Abidin, Imran, Tamin, Syahidah Syed, Martínez, Eduardo Rivera, Soto Nieto, Gabriel Israel, van der Meer, Jan T.M., Chambers, Stephen, Holland, David, Morris, Arthur, Raymond, Nigel, Read, Kerry, Murdoch, David R., Dragulescu, Stefan, Ionac, Adina, Mornos, Cristian, Butkevich, O.M., Chipigina, Natalia, Kirill, Ozerecky, Vadim, Kulichenko, Vinogradova, Tatiana, Edathodu, Jameela, Halim, Magid, Liew, Yee-Yun, Tan, Ru-San, Lejko-Zupanc, Tatjana, Logar, Mateja, Mueller-Premru, Manica, Commerford, Patrick, Commerford, Anita, Deetlefs, Eduan, Hansa, Cass, Ntsekhe, Mpiko, Almela, Manel, Ambrosioni, Juan, Azqueta, Manuel, Brunet, Merce, Castro, Pedro, De Lazzari, Elisa, Falces, Carlos, Fuster, David, Fita, Guillermina, Garcia- de- la- Maria, Cristina, Garcia-Gonzalez, Javier, Gatell, Jose M., Llopis, Jaume, Marco, Francesc, Miró, José M., Moreno, Asuncion, Ortiz, José, Ninot, Salvador, Paré, J. Carlos, Pericas, Juan M., Quintana, Eduard, Ramirez, Jose, Rovira, Irene, Sandoval, Elena, Sitges, Marta, Tellez, Adrian, Tolosana, José M., Vidal, Barbara, Vila, Jordi, Anguera, Ignasi, Font, Bernat, Guma, Joan Raimon, Bermejo, Javier, Bouza, Emilio, Garcia Fernández, Miguel Angel, Gonzalez-Ramallo, Victor, Marín, Mercedes, Muñoz, Patricia, Pedromingo, Miguel, Roda, Jorge, Rodríguez-Créixems, Marta, Solis, Jorge, Almirante, Benito, Fernandez-Hidalgo, Nuria, Tornos, Pilar, de Alarcón, Arístides, Parra, Ricardo, Alestig, Eric, Johansson, Magnus, Olaison, Lars, Snygg-Martin, Ulrika, Pachirat, Orathai, Pachirat, Pimchitra, Pussadhamma, Burabha, Senthong, Vichai, Casey, Anna, Elliott, Tom, Lambert, Peter, Watkin, Richard, Eyton, Christina, Klein, John L., Bradley, Suzanne, Kauffman, Carol, Bedimo, Roger, Chu, Vivian H., Corey, G. Ralph, Crowley, Anna Lisa, Douglas, Pamela, Drew, Laura, Fowler, Vance G., Holland, Thomas, Lalani, Tahaniyat, Mudrick, Daniel, Samad, Zaniab, Sexton, Daniel, Stryjewski, Martin, Wang, Andrew, Woods, Christopher W., Lerakis, Stamatios, Cantey, Robert, Steed, Lisa, Wray, Dannah, Dickerman, Stuart A., Bonilla, Hector, DiPersio, Joseph, Salstrom, Sara-Jane, Baddley, John, Patel, Mukesh, Peterson, Gail, Stancoven, Amy, Levine, Donald, Riddle, Jonathan, Rybak, Michael, Cabell, Christopher H., Pericàs, Juan M., Jiménez-Exposito, Maria Jesús, Kourany, Wissam M., Montagna-Mella, Rodrigo, Mestres, Carlos A., de Lazzari, Elisa, Fowler, Vance G., Jr., and Miró, Jose M.

Published
2021
Full Text
View/download PDF

3. Heterogeneous Vancomycin-Intermediate Susceptibility Phenotype in Bloodstream Methicillin-Resistant Staphylococcus aureus Isolates from an International Cohort of Patients with Infective Endocarditis: Prevalence, Genotype, and Clinical Significance

Author

Bae, In-Gyu, Federspiel, Jerome J., Miró, José M., Woods, Christopher W., Park, Lawrence, Rybak, Michael J., Rude, Thomas H., Bradley, Suzanne, Bukovski, Suzana, de la Maria, Cristina Garcia, Kanj, Souha S., Korman, Tony M., Marco, Francesc, Murdoch, David R., Plesiat, Patrick, Rodriguez-Creixems, Marta, Reinbott, Porl, Steed, Lisa, Tattevin, Pierre, Tripodi, Marie-Françoise, Newton, Karly L., Corey, G. Ralph, and Fowler, Vance G.

Published
2009

8. Clinical Presentation, Etiology, and Outcome of Infective Endocarditis in the 21st Century: The International Collaboration on Endocarditis–Prospective Cohort Study

Author

Murdoch, David R., Corey, Ralph G., Hoen, Bruno, Miró, José M., Fowler, Vance G., Jr, Bayer, Arnold S., Karchmer, Adolf W., Olaison, Lars, Pappas, Paul A., Moreillon, Philippe, Chambers, Stephen T., Chu, Vivian H., Falcó, Vicenç, Holland, David J., Jones, Philip, Klein, John L., Raymond, Nigel J., Read, Kerry M., Tripodi, Marie Francoise, Utili, Riccardo, Wang, Andrew, Woods, Christopher W., and Cabell, Christopher H.

Published
2009
Full Text
View/download PDF

9. Current features of infective endocarditis in elderly patients: results of the International Collaboration on Endocarditis Prospective Cohort Study

Author

Durante-Mangoni, Emanuele, Bradley, Suzanne, Selton-Suty, Christine, Tripodi, Marie-Francoise, Barsic, Bruno, Bouza, Emilio, Cabell, Christopher H., de Oliveira Ramos, Auristela Isabel, Fowler, Vance, Jr., Hoen, Bruno, Konecny, Pam, Moreno, Asuncion, Murdoch, David, Pappas, Paul, Sexton, Daniel J., Spelman, Denis, Tattevin, Pierre, Miro, Jose M., van der Meer, Jan T.M., and Utili, Riccardo

Subjects
Infective endocarditis -- Development and progression, Infective endocarditis -- Demographic aspects, Infective endocarditis -- Care and treatment, Aged patients -- Physiological aspects, Aged patients -- Research, Health
Published
2008

15. In vitro activity effects of twelve antibiotics alone and in association against twenty-seven Enterococcus faecalis strains isolated from Italian patients withinfective endocarditis: high in vitro synergistic effect of the associationceftriaxone-fosfomycin

Author

Farina, C, Russello, G, Chinello, P, Pasticci, Mb, Raglio, A, Ravasio, V, Rizzi, M, Scarparo, C, Vailati, F, Suter, F, Collaborators: Suter F, Italian Infective Endocarditis Study G. r. o. u. p., Biglino, A, Carosi, G, Persiani, M, Utili, R, Tripodi, MARIE FRANCOISE, Minoli, L, Petrosillo, N, Venditti, M, Vaglia, A, Crapis, M, Grossi, P, and Concia, E.

Published
2011

16. Management of cardiac implantable electronic device infections: recommendations from a study panel

Author

Durante Mangoni, E, Carbonara, S, Iacobello, C, Tripodi, MARIE FRANCOISE, Carretta, A, Caprioli, V, Pellegrino, P, Di Biase, M, Favale, S, Santantonio, Ta, Esposito, Silvano, Nappi, G, Angarano, G, Utili, R., DURANTE MANGONI, Emanuele, Carbonara, S, Iacobello, C, Tripodi, Mf, Carretta, A, Caprioli, V, Pellegrino, P, Di Biase, M, Favale, S, Santantonio, Ta, Esposito, S, Nappi, Gianantonio, Angarano, G, and Utili, Riccardo

Published
2011

17. In vitro activity of multiple antibiotic combinations against Nocardia: relationship with a short-term treatment strategy in heart transplant recipients with pulmonary nocardiosis

Author

Tripodi, MARIE FRANCOISE, Durante Mangoni, E, Fortunato, R, Cuccurullo, S, Mikami, Y, Farina, C, Utili, R., Tripodi, Mf, DURANTE MANGONI, Emanuele, Fortunato, R, Cuccurullo, S, Mikami, Y, Farina, C, and Utili, Riccardo

Subjects
Adult, Lung Diseases, Male, Time Factors, Nocardia Infections, Microbial Sensitivity Tests, Middle Aged, Nocardia, Anti-Bacterial Agents, Treatment Outcome, Disk Diffusion Antimicrobial Tests, Heart Transplantation, Humans, Drug Therapy, Combination, Female
Abstract

Pulmonary nocardiosis (PN) chiefly affects immunocompromised patients, particularly transplant recipients. Cotrimoxazole is still the mainstay of treatment, but it is associated with nephro- and myelo-toxicity, and can show unpredictable activity against Nocardia isolates.Over a 20-year period, Nocardia isolates were identified from 12 heart transplant (HTx) recipients with PN. The in vitro activity of various antibacterials, alone or in combination, was assessed using disk-diffusion, minimal inhibitory concentration (MIC), and time-kill methodology. The in vitro results were compared with the clinical outcome of the patients.Seven different Nocardia strains were identified. Disk diffusion and MIC determinations showed that all isolates were susceptible to amikacin, netilmicin, and linezolid, and that moxifloxacin was the most active of the fluoroquinolones. All but 1 of the isolates were susceptible to imipenem. Time-kill studies showed that imipenem/amikacin and imipenem/moxifloxacin combinations were bactericidal for most isolates. Of 12 patients who received 3-4 weeks' intravenous (IV) treatment with amikacin or ciprofloxacin in combination with a beta-lactam, followed by 1-3 months' oral cotrimoxazole, moxifloxacin, or linezolid, 11 were cured; 1 patient died, but not related to Nocardia.Initial PN treatment in HTx recipients can be successfully carried out with bactericidal combinations such as imipenem plus amikacin or moxifloxacin, administered IV for 3-4 weeks. Within 1 month, a significant clinical and radiological improvement may be observed. In our experience, a3 month oral regimen with cotrimoxazole, moxifloxacin, or doxycycline may then be used. This may allow a reduction of side effects and treatment-related burden, without any recurrence.

Published
2010

18. Current trends in infective endocarditis in Italy: report on 852 cases from the multicenter, prospective SEI study

Author

Ravasio, V., Rizzi, M., Stellini, R., Spoladore, G, Durante Mangoni, E., Tripodi, MARIE FRANCOISE, Barbaro, F., Petrosillo, N., Venditti, M., Crapis, M., Suter, F., Utili, R., Ravasio, V, Rizzi, M, Stellini, R, Spoladore, G, DURANTE MANGONI, Emanuele, Tripodi, M. F., Barbaro, F, Petrosillo, N, Venditti, M, Crapis, M, Suter, F, and Utili, Riccardo

Abstract

abs#023

Published
2009

19. Candida infective endocarditis: report of 15 cases from a prospective multicenter study

Author

Falcone, M, Barzaghi, N, Carosi, G, Grossi, P, Minoli, L, Ravasio, V, Rizzi, M, Suter, F, Utili, R, Viscoli, C, Venditti, M, Collaborators: Biglino A, Italian Study on E. n. d. o. c. a. r. d. i. t. i. s., Crivelli, P, Stellini, R, Magri, S, Del Bono, V, Vitale, F, Scalzini, A, Gattuso, G, Durante Mangoni, E, Ragone, E, Cuccurullo, S, Tripodi, MARIE FRANCOISE, Spoladore, G, Pasticci, Mb, Martinelli, L, Mal, Uo, Petrosillo, N, Chinello, P, Delle Foglie, P, Vaglia, A, Viale, P, Crapis, M, Tambini, R, Tomasello, L, Pellizzer, Gp, Nicolin, R, Concia, E, Del Bravo, P, Tedesco, A., Falcone, M, Barzaghi, N, Carosi, G, Grossi, P, Minoli, L, Ravasio, V, Rizzi, M, Suter, F, Utili, Riccardo, Viscoli, C, Venditti, M, and ITALIAN STUDY ON, Endocarditis

Subjects
Adult, Male, medicine.medical_specialty, Antifungal Agents, Prosthesis-Related Infections, Adolescent, Candida, infective endocarditis, italy, Echinocandins, Lipopeptides, Young Adult, chemistry.chemical_compound, Caspofungin, Epidemiology, medicine, Humans, Endocarditis, Prospective Studies, Prosthesis-Related Infection, Child, Prospective cohort study, Aged, Aged, 80 and over, yeast endocarditis, Native Valve Endocarditis, business.industry, Mortality rate, Candidiasis, General Medicine, Middle Aged, medicine.disease, Surgery, chemistry, Child, Preschool, Heart Valve Prosthesis, Infective endocarditis, Female, business
Abstract

Candida species are an uncommon cause of infective endocarditis (IE). Given the rarity of this infection, the epidemiology, prognosis, and optimal therapy of Candida IE are poorly defined. We conducted a prospective, observational study at 18 medical centers in Italy, including all consecutive patients with a definite diagnosis of IE admitted from January 2004 through December 2007.A Candida species was the causative organism in 8 cases of prosthetic valve endocarditis (PVE), 5 cases of native valve endocarditis (NVE), 1 case of pacemaker endocarditis, and 1 case of left ventricular patch infection. Candida species accounted for 1.8% of total cases, and for 3.4% of PVE cases. Most patients (86.6%) had a health care-associated infection. PVE associated with a health care contact occurred after a median of 225 days from valve implantation. Ten patients (66.6%) were treated with caspofungin alone or in combination with other antifungal drugs. The overall mortality rate was 46.6%. Mortality was higher in patients with PVE (5 of 8 cases, 62.5%) than in patients with NVE (2 of 5 patients, 40%). A better outcome was observed in patients treated with a combined medical and surgical therapy.Candida IE should be classified as an emerging infectious disease, usually involving patients with intravascular prosthetic devices, and associated with substantial related morbidity and mortality. Candida PVE usually is a late-onset disease, which becomes clinically evident even several months after an initial episode of transient candidemia.

Published
2009

21. Reply to Klein

Author

Tripodi, Marie-Francoise, Adinolfi, Luigi Elio, and Utili, Riccardo

Subjects
Health, Health care industry
Published
2004

25. Phylogenetic Analysis of Viridans Group Streptococci Causing Endocarditis

Author

Simmon, Keith E., primary, Hall, Lori, additional, Woods, Christopher W., additional, Marco, Francesc, additional, Miro, Jose M., additional, Cabell, Christopher, additional, Hoen, Bruno, additional, Marin, Mercedes, additional, Utili, Riccardo, additional, Giannitsioti, Efthymia, additional, Doco-Lecompte, Thanh, additional, Bradley, Suzanne, additional, Mirrett, Stanley, additional, Tambic, Arjana, additional, Ryan, Suzanne, additional, Gordon, David, additional, Jones, Phillip, additional, Korman, Tony, additional, Wray, Dannah, additional, Reller, L. Barth, additional, Tripodi, Marie-Francoise, additional, Plesiat, Patrick, additional, Morris, Arthur J., additional, Lang, Selwyn, additional, Murdoch, David R., additional, and Petti, Cathy A., additional

Published
2008
Full Text
View/download PDF

31. [Prosthetic valve endocarditis. Review of 57 cases]

Author

Ruggiero, G, Adinolfi, Le, Utili, R, Rosario, P, Tripodi, MARIE FRANCOISE, Attanasio, V., Ruggiero, G, Adinolfi, Luigi Elio, Utili, Riccardo, Rosario, P, Tripodi, Mf, and Attanasio, V.

Subjects
Adult, Male, Prosthesis-Related Infections, Adolescent, Heart Valve Prosthesis, Humans, Female, Endocarditis, Bacterial, Middle Aged, Child, Aged, Anti-Bacterial Agents
Published
1991

42. Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon.

Author

Adinolfi LE, Durante-Mangoni E, Salzillo M, Marrone A, Tripodi MF, Restivo L, Merola A, Zampino R, Ruggiero G, Adinolfi, Luigi E, Durante-Mangoni, Emanuele, Salzillo, Marta, Marrone, Aldo, Tripodi, Marie-Francoise, Restivo, Luciano, Merola, Antonietta, Zampino, Rosa, and Ruggiero, Giuseppe

Abstract

Treatments for chronic hepatitis C (CHC) patients intolerant to pegylated interferons (peg-IFNs) are lacking. Thus, such patients remain at high risk of developing an advanced and decompensated liver disease. Leukocyte IFN-alpha (Le-IFN-alpha) seems to possess a safer profile than other natural and recombinant a-interferons, but no information is available for peg-IFN intolerant patients. Accordingly, we evaluated the safety and efficacy of Le-IFN-alpha in patients intolerant to peg-IFNs. Twenty-five consecutive CHC patients intolerant to peg-IFNs were prospectively enrolled. HCV genotype 1 was present in 80% and cirrhosis in 68% of cases. Thirteen patients (52%) had thrombocytopenia. Le-IFN-alpha (3 MU three times a week) was administered for 48 weeks plus ribavirin 800 or 1,000 mg/day for HCV genotype 2/3 and 1, respectively. The follow-up was at 24 weeks. Compliance with treatment was satisfactory if the patient received 80% of the therapeutic regimen. An intention-to-treat analysis was done. Eighty-eight percent of CHC patients completed the prescribed treatment course with Le-IFN-alpha. In these patients the side effects, when observed, were mild to moderate, and did not require Le-IFN-alpha dose adjustment. Le-IFN-alpha showed significantly less hematological toxicity than peg-IFN (4 vs 48%; P<0.02). The overall sustained virologic response was 32%, i.e., 24% for cirrhotics and 50% for CHC, and 25% for genotype 1 and 60% for genotypes 2/3. The data indicate that Le-IFN-alpha plus ribavirin is a useful and effective treatment for CHC patients who are intolerant to peg-IFNs. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results